Intra-hepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy
Giuliana AMADDEO,
Cong Trung NGUYEN,
P Maille,
S Mule,
Alain LUCIANI,
Camilia MACHOU,
Aurélie RODRIGUES,
H Regnault,
A Mallat,
A Laurent,
Fouad LAFDIL,
Christophe HEZODE,
Jean-Michel PAWLOTSKY,
Julien CALDERARO,
Liver Int 24/08/2019;- : - 10.1111/liv.14226
Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder
JB Trabut,
C Barrault,
H Charlot,
D Carmona,
A Bourdel,
M Benslimane,
Murielle FRANCOIS,
W Kini-Matondo,
R Causse,
F Roudot-Thoraval,
Christophe HEZODE,
J Addict Med 01/09/2018;12(5) : 346-352 10.1097/ADM.0000000000000415
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
M Puoti,
GR Foster,
S Wang,
D Mutimer,
E Gane,
C Moreno,
TT Chang,
SS Lee,
R Marinho,
JF Dufour,
S Pol,
Christophe HEZODE,
SC Gordon,
SI Strasser,
PJ Thuluvath,
Z Zhang,
S Lovell,
T Pilot-Matias,
FJ Mensa,
J Hepatol. 01/08/2018;69(2) : 293-300 10.1016/j.jhep.2018.03.007. 16/03/2018
Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure
F Poordad,
S Pol,
A Asatryan,
M Buti,
D Shaw,
Christophe HEZODE,
F Felizarta,
RW Reindollar,
SC Gordon,
S Pianko,
MW Fried,
D Bernstein,
J Gallant,
CW Lin,
Y Lei,
TI Ng,
P Krishnan,
S Kopecky-Bromberg,
J Kort,
FJ Mensa,
Hepatology. 01/06/2018;67(4) : 1253-1260 10.1002/hep.29671 30/01/2018
Long-Term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis.
P Cacoub,
SN Si Ahmed,
Y Ferfar,
S Pol,
D Thabut,
Christophe HEZODE,
L Alric,
C Comarmond,
G Ragab,
L Quartuccio,
M Hegazy,
T Poynard,
M Resche-Rigon,
D Saadoun,
Clin Gastroenterol Hepatol. 29/05/2018;pii: S1542-3565(18) : 30553-6 10.1016/j.cgh.2018.05.021
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies
Christophe HEZODE,
N Reau,
ES Svarovkaia,
BP Doehle,
R Shanmugam,
H Dvory-Sobol,
C Hedskog,
J McNally,
A Osinusi,
DM Brainard,
MD Miller,
H Mo,
SK Roberts,
JG O'Leary,
SD Shafran,
S Zeuzem,
J Hepatol 01/05/2018;68(5) : 895-903 10.1016/j.jhep.2017.11.032. 06/12/2017
Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE
V De Ledinghen,
C Laforest,
Christophe HEZODE,
S Pol,
A Renault,
L Alric,
D Larrey,
S Metivier,
A Tran,
C Jezequel,
D Samuel,
F Zoulim,
C Tual,
A Pailhe,
S Gibowski,
M Bourliere,
E Bellissant,
Jean-Michel PAWLOTSKY,
Clin Infect Dis. 19/03/2018;66(7) : 1013-1018 10.1093/cid/cix916.
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study
V De Ledinghen,
C Laforest,
Christophe HEZODE,
S Pol,
A Renault,
L Alric,
D Larrey,
S Metivier,
A Tran,
C Jezequel,
D Samuel,
F Zoulim,
C Tual,
A Pailhe,
S Gibowski,
M Bourliere,
E Bellissant,
Jean-Michel PAWLOTSKY,
Clin Infect Dis. 19/03/2018;66(7) : 1013-1018 10.1093/cid/cix916.